From medicine to business and wellness
NYS Medicaid Fee-for-Service Policy Guidance for SPRAVATO® (Esketamine) Nasal Spray
The New York State (NYS) Medicaid Drug Utilization Review (DUR) Board recommended some criteria for Spravato® nasal spray under Pharmacy and Medical Benefit. This came into effect on August 11, 2022, which is mentioned hereafter:
Subscribe to get the latest posts sent to your email.
Affinity has announced that, pending regulatory approval, Affinity’s assets will be acquired by Molina Healthcare of New York, Inc. and…
Effective April 1, 2024, a significant enhancement to healthcare accessibility is set to unfold within the New York State (NYS)…
Prior authorization is an eligibility verification process, which requires health care providers to obtain approval from a health insurance provider…